Decibel Therapeutics Inc Quick Ratio (DBTX) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Decibel Therapeutics Inc   (NASDAQ: DBTX)

Decibel Therapeutics Inc 's Quick Ratio

DBTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 2.95 a new company low.

Within Major Pharmaceutical Preparations industry 331 other companies have achieved higher Quick Ratio than Decibel Therapeutics Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 809 to 1149.

Explain Quick Ratio?
How much Cash & cash equivalents DBTX´s has?
What are DBTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DBTX Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 16.19 % 28 % 223.19 % 1188.53 % 968.38 %
Y / Y Cash & cash equivalent Change -37.68 % -34.59 % -29.71 % -22.2 % -19.34 %
Quick Ratio MRQ 2.95 3.79 4.66 4.79 5.49
DBTX's Total Ranking # 1149 # 809 # 484 # 844 # 667
Seq. Current Liabilities Change 14.66 % 3.28 % -3.99 % 2.19 % 26.31 %
Seq. Cash & cash equivalent Change -10.96 % -15.9 % -6.6 % -10.91 % -6.54 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 332
Healthcare Sector # 566
Overall Market # 1149


Quick Ratio Statistics
High Average Low
182.08 40.03 2.95
(Mar 31 2021)   (Jun 30 2023)




Financial Statements
Decibel Therapeutics Inc 's Current Liabilities $ 27 Millions Visit DBTX's Balance sheet
Decibel Therapeutics Inc 's Cash & cash equivalent $ 78 Millions Visit DBTX's Balance sheet
Source of DBTX's Sales Visit DBTX's Sales by Geography


Cumulative Decibel Therapeutics Inc 's Quick Ratio

DBTX's Quick Ratio for the trailling 12 Months

DBTX Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 92.14 % 216.7 % 629.46 % 650.77 % 547.42 %
Y / Y Cash & cash equivalent TTM Growth -30.75 % -26.21 % -24.41 % -2.85 % 40.95 %
Quick Ratio TTM 4 4.68 5.49 7.3 11.11
Total Ranking TTM # 3828 # 3744 # 3649 # 524 # 3580
Seq. Current Liabilities TTM Growth 4.03 % 5.84 % 21.74 % 43.34 % 71.47 %
Seq. Cash & cash equivalent TTM Growth -11.01 % -9.76 % -8.48 % -5.78 % -5.17 %

Quick ratio ranking by company, industry and sector >> Back to DBTX Financial Strength Comparisons >> Go to Compare DBTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2023 to $26.58 millions, cumulative Quick Ratio decreased to 4 below the Decibel Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 533 other companies have achieved higher Quick Ratio than Decibel Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 3744 to 3828.

Explain Quick Ratio?
How much Cash & cash equivalents DBTX´s has?
What are DBTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 534
Healthcare Sector # 1061
Within the Market # 3828


trailing twelve months Quick Ratio Statistics
High Average Low
9.16 6.38 4
(Dec 31 2021)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Nektar Therapeutics  8.08 $ 409.432  Millions$ 50.694  Millions
Cypherpunk Technologies Inc   8.07 $ 91.415  Millions$ 11.326  Millions
Lumos Pharma Inc   7.99 $ 50.851  Millions$ 6.366  Millions
Longboard Pharmaceuticals Inc   7.98 $ 63.047  Millions$ 7.901  Millions
Pulmatrix Inc   7.96 $ 25.791  Millions$ 3.239  Millions
Lixte Biotechnology Holdings Inc   7.95 $ 2.913  Millions$ 0.367  Millions
Pds Biotechnology Corp  7.67 $ 60.625  Millions$ 7.904  Millions
Compass Pathways Plc  7.62 $ 148.485  Millions$ 19.489  Millions
Vera Therapeutics Inc   7.46 $ 181.021  Millions$ 24.275  Millions
Ligand Pharmaceuticals Incorporated  7.45 $ 219.041  Millions$ 29.388  Millions
Capricor Therapeutics inc   7.36 $ 37.793  Millions$ 5.134  Millions
Arcutis Biotherapeutics Inc   7.33 $ 268.671  Millions$ 36.659  Millions
Prf Technologies Ltd   7.32 $ 6.162  Millions$ 0.842  Millions
Marinus Pharmaceuticals Inc   7.29 $ 175.336  Millions$ 24.047  Millions
Metavia Inc   7.20 $ 28.688  Millions$ 3.983  Millions
Bolt Biotherapeutics Inc   7.14 $ 125.866  Millions$ 17.618  Millions
Clearside Biomedical Inc   7.12 $ 35.005  Millions$ 4.915  Millions
Cormedix Inc   7.09 $ 52.401  Millions$ 7.387  Millions
Puretech Health Plc  7.05 $ 362.261  Millions$ 51.370  Millions
Opus Genetics Inc   6.94 $ 39.999  Millions$ 5.761  Millions
Theravance Biopharma inc   6.82 $ 167.451  Millions$ 24.546  Millions
Ngm Biopharmaceuticals Inc   6.81 $ 193.544  Millions$ 28.423  Millions
Oragenics Inc   6.81 $ 6.474  Millions$ 0.951  Millions
Sagimet Biosciences inc   6.80 $ 18.508  Millions$ 2.723  Millions
Assembly Biosciences Inc   6.78 $ 59.831  Millions$ 8.831  Millions
Calcimedica Inc   6.77 $ 19.084  Millions$ 2.817  Millions
Hoth Therapeutics Inc   6.74 $ 11.569  Millions$ 1.716  Millions
Context Therapeutics Inc   6.70 $ 25.138  Millions$ 3.750  Millions
Abcellera Biologics Inc   6.69 $ 795.694  Millions$ 118.905  Millions
Cohbar Inc   6.57 $ 12.311  Millions$ 1.874  Millions

Date modified: 2026-08-29T17:43:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.